Novartis sets higher expectations for key cancer drugs Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 20 November, 2025

The hematology sector heads into ASH under pressure, with data that could reshape R&D strategies and investment decisions across blood disorders. Join our expert analysis of the year’s most consequential readouts. Sign up today.

presented by Where ded­i­ca­tion de­liv­ers ex­cel­lence in bi­o­log­ics

spotlight Live at 1 p.m. ET: The drug industry’s Mr. Reality Check, Derek Lowe

news Aspen gets $115M for Parkinson's cell therapy, potential IPO in sight next year After Phase 3 hit, Innovent to seek China approval of high-dose obesity shot it got from Lilly Novartis raises the sales bar for key cancer drugs, tweaks yearly growth guidance Life sciences sector ‘has lost confidence’ in the UK, committee member says Ensoma halves workforce as genetic medicines startup enters clinic

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium coworking and meeting space just steps from the action. Save $200 with Early Bird rates — reserve your spot today.

endpoints pharma Pfizer CFO says drugmaker will 'supplement' Metsera deal as part of broader obesity ambitions Flagship's Tessera to start first human trial using new gene writing platform US-backed group says new tuberculosis treatment worked in a Phase 2 study FDA approves Bayer’s HER2-mutated lung cancer drug, heating up rivalry with Boehringer PBMs, FTC clash in court over agency’s in-house insulin challenge

in case you missed it 1. David Liu’s lab devises one-size-fits-many prime editing, but obstacles to broad use in humans persist 2. Agios' sickle cell trial falls short as drug doesn't appear to help patient pain crises 3. Protara trumpets small rare disease dataset in children for cell therapy 4. News Briefing Pfizer's antibody pact with Nona Biosciences; Epkinly's label expansion 5. Merck says once-daily HIV drug combo succeeds in another Phase 3 6.